# Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

> **NCT06155331** · PHASE2 · COMPLETED · sponsor: **Tanta University** · enrollment: 44 (actual)

## Conditions studied

- Breast Cancer Stage 2 and 3

## Interventions

- **DRUG:** Fenofibrate
- **OTHER:** Placebo
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06155331
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155331, "Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06155331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*